At the request of Mark Smith, who is the force behind Trade Villa, I am posting this information to help clarify how to participate in this Yahoo Group.
A
Note from Mark the sysop of TradeVilla.
As per the previous TradeVilla post, Tradevilla is a selective group catering primarily to high net worth individuals and institutions who/which follow AllAllan trades among other possible methodologies.
It is selective in its membership and requires full disclosure to participate in it. It also keeps this blog from being clogged with a lot of asset allocation posts, etc. and allows the readership to exchange ideas in a direct and efficient format.
All who apply for TradeVilla membership need to include in the application email the answers to the following questions to determine suitability for entry into the group.
When you apply for membership at TradeVilla, your reply must include:
Your Full Name:
Your Location:
Whether you are an institution or individual:
The approximate Amount of Capital you have invested in AllAllan Trades and elsewhere:
A description of how you trade AllAllan and other methodologies:
What You Hope to Achieve By Joining TradeVilla:
What your tangible and intangible contributions to TradeVilla can be:
A review will be made of your application at that time.
Thanks!
Mark Smith, TradeVilla
Thursday, February 28, 2008
Wednesday, February 27, 2008
VLNC
I recommended VLNC throughout 2006-2007 at prices between $1-$2. VLNC is up over $3.50 today. That's a minimum of a 75% gain, more to come if you hold on.
I have an ego, too.
A
I have an ego, too.
A
Tuesday, February 26, 2008
Trade Villa
Trying to post a profitable stock trading blog has it's own challenges and rewards. I have heard, mostly through private email, although some through public Comments, that some of my readers have done quite well with ideas posted from time to time on this Blog. A continuing thread in most of these Comments and emails is what else have I got? In other words, "More trades and more strategy, Please."
Posting trading ideas for the general readership, not knowing much about who you are or how you trade, what your temperament, discipline or your level of risk aversion, limits the number and nature of trading ideas I post. But one of my readers, someone who has been around this Blog a long time and according to him, has made significant profits from trade ideas posted on AllAllan, asked me a while back if I would be willing to post some ideas and/or participate in a sub-group of traders and investors that would be limited in number and sophistication so that more trading ideas, some of which may not be suitable for just anyone, could be proposed and discussed.
Asset allocation plays an important role here and its discussion would really encumber this board especially since there is a diverse readership applying various strategies. Thus, I would like to redirect those discussions as well.
So I am pointing all readers, but mostly institutions and individuals with larger amounts of investment capital, toward an independent and private group set up by “Mark,” one of my long time readers and larger dollar value investors, called “TradeVilla.”
My daily blog hits are from 350-700 per day and many of those are likely from professionals, institutional investors or from individuals who are large enough to qualify as institutions.
TradeVilla has been around for a couple of months and I am a member myself but have no control over its membership or the posts there other than my own.
I post some trades there that I do not post here and that are geared toward higher dollar value investments, usually put on by institutional investors, and require a more highly diversified portfolio to trade. Thus, TradeVilla is, by natural evolution, geared towards larger, institutional investors with higher dollar value portfolios.
In other words, this is my heads-up to investors, especially those who have larger asset allocations, to TraveVilla. It is found at this link: TradeVilla.
If you would like to subscribe to this Yahoo Group:
1. Visit:
http://groups.yahoo.com/group/TradeVilla/join
-OR-
2. Send an email to TradeVilla-subscribe@yahoogroups.com
All members are “vetted” by the sysop (not me) and asset allocation discussions for larger investors can take place there. Of course, this is a private, unlisted Yahoo Group and is free of charge like this Blog. But is a natural extension of it especially for larger investors/ institutions.
Hopefully, that will alleviate some of the issues described in the issues listed above as larger investors can compare asset allocation notes with each other and exchange more detailed ideas with each other, in a private and controlled forum dedicated to the more elite AllAllan traders.
Posting trading ideas for the general readership, not knowing much about who you are or how you trade, what your temperament, discipline or your level of risk aversion, limits the number and nature of trading ideas I post. But one of my readers, someone who has been around this Blog a long time and according to him, has made significant profits from trade ideas posted on AllAllan, asked me a while back if I would be willing to post some ideas and/or participate in a sub-group of traders and investors that would be limited in number and sophistication so that more trading ideas, some of which may not be suitable for just anyone, could be proposed and discussed.
Asset allocation plays an important role here and its discussion would really encumber this board especially since there is a diverse readership applying various strategies. Thus, I would like to redirect those discussions as well.
So I am pointing all readers, but mostly institutions and individuals with larger amounts of investment capital, toward an independent and private group set up by “Mark,” one of my long time readers and larger dollar value investors, called “TradeVilla.”
My daily blog hits are from 350-700 per day and many of those are likely from professionals, institutional investors or from individuals who are large enough to qualify as institutions.
TradeVilla has been around for a couple of months and I am a member myself but have no control over its membership or the posts there other than my own.
I post some trades there that I do not post here and that are geared toward higher dollar value investments, usually put on by institutional investors, and require a more highly diversified portfolio to trade. Thus, TradeVilla is, by natural evolution, geared towards larger, institutional investors with higher dollar value portfolios.
In other words, this is my heads-up to investors, especially those who have larger asset allocations, to TraveVilla. It is found at this link: TradeVilla.
If you would like to subscribe to this Yahoo Group:
1. Visit:
http://groups.yahoo.com/group/TradeVilla/join
-OR-
2. Send an email to TradeVilla-subscribe@yahoogroups.com
All members are “vetted” by the sysop (not me) and asset allocation discussions for larger investors can take place there. Of course, this is a private, unlisted Yahoo Group and is free of charge like this Blog. But is a natural extension of it especially for larger investors/ institutions.
Hopefully, that will alleviate some of the issues described in the issues listed above as larger investors can compare asset allocation notes with each other and exchange more detailed ideas with each other, in a private and controlled forum dedicated to the more elite AllAllan traders.
Friday, February 22, 2008
MOSY
This is another heads-up from Don Wolanchuk:
"Follow the money."
Carl Berg, the insider here, is also the insider behind Valence Technology, which has more then doubled in the past month.
A
"Follow the money."
Carl Berg, the insider here, is also the insider behind Valence Technology, which has more then doubled in the past month.
A
Wednesday, February 20, 2008
On a Personal Note
I'm in South Carolina, attending the final basketball games of my youngest daughter's high school basketball experience. Last night was the Regional Tournament Championship games. My daughter's team, undefeated in conference play, 8-0, lost the tournament championship by two points. Now on to the State Tournament.
At the end of the evening they handed out the trophies and individual achievement awards. This was the end of basketball for my two daughters that started way back in the nineties and went through a JV team with only six players, through driving untold miles to remote gyms spread out across the "Low Country," to private schools that make up South Carolina Region II, through both girls starting for their varsity teams to now, the final moments of play for my youngest daughter in her home gym.
Near the end of the ceremony, out if the blue, unexpected, a burst of pride and culmination, came this:
The fifth and final player selected and named to the Region II All-Tournament Girls Varsity Team:
Alana Harris
Sometimes in the end, everything just seems worth it all.
A
At the end of the evening they handed out the trophies and individual achievement awards. This was the end of basketball for my two daughters that started way back in the nineties and went through a JV team with only six players, through driving untold miles to remote gyms spread out across the "Low Country," to private schools that make up South Carolina Region II, through both girls starting for their varsity teams to now, the final moments of play for my youngest daughter in her home gym.
Near the end of the ceremony, out if the blue, unexpected, a burst of pride and culmination, came this:
The fifth and final player selected and named to the Region II All-Tournament Girls Varsity Team:
Alana Harris
Sometimes in the end, everything just seems worth it all.
A
Tuesday, February 19, 2008
NNVC
The market cap of NNVC is about $50M. Read today's press release, these tests were made not by NNVC, but by the US Army. Now read what I have highlighted in bold. Finally, ask yourself how much longer this company will be valued at under $100M......and then how much longer it will be valued at under $500M?
A
Nanoviricides Found Highly Effective against Ebola by USAMRIID
Tuesday February 19, 7:00 am ET
Broad-spectrum Nanoviricides Demonstrated to Have Excellent Efficacy in Cell Culture Studies
WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced today that the broad-spectrum nanoviricides™ drug candidates were found to be highly effective against the deadly Ebola virus in initial cell culture studies by scientists at the United States Army Medical Research Institute of Infectious Diseases (USAMRIID).
“The fact that the same drug candidates that were highly effective against common influenza and rabies in animal studies and bird flu (H5N1) in cell culture studies were also found to be highly effective against the deadly Ebola virus clearly indicates that these nanoviricides are truly broad-spectrum,” said Eugene Seymour, MD, MPH, CEO of the Company, about the results.
“We have identified common mechanisms by which these very different types of viruses bind to cells and enter cells. We have designed the nanoviricides to display the same features that these viruses look for on the host cell. Our nanoviricides essentially mimic the host cell. We believe this results in fooling the virus to bind to the nanoviricide and be destroyed,” said Anil R. Diwan, Ph.D., President of the Company, adding, “We now have a phenomenal streak of successes of this biomimetic technology as broad-spectrum antivirals.”
Animal studies to test the efficacy of these nanoviricides drug candidates against Ebola infection will be undertaken shortly, according to USAMRIID scientists.
USAMRIID and NanoViricides entered into a Material Transfer Agreement (MTA) in October, 2007. The resulting joint R&D effort enables USAMRIID scientists to test the efficacy of several NanoViricides, Inc. anti-viral nanomedicines against deadly hemorrhagic fever viruses at the Ft. Detrick, Maryland BSL4 facilities.
It is hoped that success against the deadly Ebola virus will lead to further success against other virulent pathogens such as hanta viruses, Marburg virus, Junin virus, Machupo virus, and Rift Valley fever virus. There are currently no FDA-approved treatment options for these diseases.
About USAMRIID
USAMRIID, located at Fort Detrick, Maryland, is the lead medical research laboratory for the U.S. Biological Defense Research Program, and plays a key role in national defense and in infectious disease research. The Institute’s mission is to conduct basic and applied research on biological threats resulting in medical solutions (such as vaccines, drugs and diagnostics) to protect the warfighter. USAMRIID is a subordinate laboratory of the U.S. Army Medical Research and Materiel Command.
The Institute is working to develop therapeutics for a number of agents, such as Ebola virus, plague, several toxins, and orthopoxviruses.
The information contained in this press release does not necessarily reflect the position or the policy of the Government and no official endorsement should be inferred.
About NanoViricides:
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide™ class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal influenza, HIV, hepatitis C, rabies, and dengue fever, among others.
A
Nanoviricides Found Highly Effective against Ebola by USAMRIID
Tuesday February 19, 7:00 am ET
Broad-spectrum Nanoviricides Demonstrated to Have Excellent Efficacy in Cell Culture Studies
WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced today that the broad-spectrum nanoviricides™ drug candidates were found to be highly effective against the deadly Ebola virus in initial cell culture studies by scientists at the United States Army Medical Research Institute of Infectious Diseases (USAMRIID).
“The fact that the same drug candidates that were highly effective against common influenza and rabies in animal studies and bird flu (H5N1) in cell culture studies were also found to be highly effective against the deadly Ebola virus clearly indicates that these nanoviricides are truly broad-spectrum,” said Eugene Seymour, MD, MPH, CEO of the Company, about the results.
“We have identified common mechanisms by which these very different types of viruses bind to cells and enter cells. We have designed the nanoviricides to display the same features that these viruses look for on the host cell. Our nanoviricides essentially mimic the host cell. We believe this results in fooling the virus to bind to the nanoviricide and be destroyed,” said Anil R. Diwan, Ph.D., President of the Company, adding, “We now have a phenomenal streak of successes of this biomimetic technology as broad-spectrum antivirals.”
Animal studies to test the efficacy of these nanoviricides drug candidates against Ebola infection will be undertaken shortly, according to USAMRIID scientists.
USAMRIID and NanoViricides entered into a Material Transfer Agreement (MTA) in October, 2007. The resulting joint R&D effort enables USAMRIID scientists to test the efficacy of several NanoViricides, Inc. anti-viral nanomedicines against deadly hemorrhagic fever viruses at the Ft. Detrick, Maryland BSL4 facilities.
It is hoped that success against the deadly Ebola virus will lead to further success against other virulent pathogens such as hanta viruses, Marburg virus, Junin virus, Machupo virus, and Rift Valley fever virus. There are currently no FDA-approved treatment options for these diseases.
About USAMRIID
USAMRIID, located at Fort Detrick, Maryland, is the lead medical research laboratory for the U.S. Biological Defense Research Program, and plays a key role in national defense and in infectious disease research. The Institute’s mission is to conduct basic and applied research on biological threats resulting in medical solutions (such as vaccines, drugs and diagnostics) to protect the warfighter. USAMRIID is a subordinate laboratory of the U.S. Army Medical Research and Materiel Command.
The Institute is working to develop therapeutics for a number of agents, such as Ebola virus, plague, several toxins, and orthopoxviruses.
The information contained in this press release does not necessarily reflect the position or the policy of the Government and no official endorsement should be inferred.
About NanoViricides:
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide™ class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal influenza, HIV, hepatitis C, rabies, and dengue fever, among others.
Monday, February 11, 2008
Monday, February 04, 2008
China Stocks
On a day where the DJIA is down close to 100 points, there are a slew of China stocks that are up over 10%.
Among them:
CHNR +23%
YGE +15%
CPSL +25%
RCH +17%
CDS +15%
FSIN +12%
Follow the money.
A
Among them:
CHNR +23%
YGE +15%
CPSL +25%
RCH +17%
CDS +15%
FSIN +12%
Follow the money.
A
Subscribe to:
Posts (Atom)